Last reviewed · How we verify

NCT05060185

The Flow Diverter for Treating Patients With Intracranial Aneurysms

Status unknown NA Last updated 29 September 2021
What this trial tests

NA trial testing the Flow Diverter in Intracranial Aneurysm in 166 participants. Status unknown.

Timeline
17 October 2021
Primary endpoint
28 February 2024
31 May 2024

Quick facts

Lead sponsorJiangsu CED Medtech Co., Ltd
PhaseNA
StatusStatus unknown
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment166
Start date17 October 2021
Primary completion28 February 2024
Estimated completion31 May 2024

Drugs / interventions tested

Conditions studied

Sponsor

Jiangsu CED Medtech Co., Ltd

Who can join

Adults 18 to 75, any sex, with Intracranial Aneurysm. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the efficacy and safety of the blood flow guide device manufactured by Jiangsu Changyida Medical Technology Co., Ltd. for endovascular embolization of intracranial aneurysms

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Intracranial Aneurysm

Currently open trials in the same condition.

Other Jiangsu CED Medtech Co., Ltd trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05060185.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing